New Perspectives in Nuclear Neurology for the Evaluation of Parkinson's Disease

Nenhuma Miniatura disponível
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2013
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
IOS PRESS
Autores
LUURTSEMA, Gert
TUMAS, Vitor
Citação
JOURNAL OF PARKINSONS DISEASE, v.3, n.3, p.301-323, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The pathophysiology of Parkinson's disease (PD) has not yet been completely elucidated. However, during the past few years, significant progress has been made in understanding the intra- and extracellular mechanisms by which proteins such as alpha-synuclein and neuroinflammatory molecules may display impaired function and/or expression in PD. Recent developments in imaging techniques based on positron emission tomography (PET) and single photon emission computed tomography (SPECT) now allow the non-invasive tracking of such molecular targets of known relevance to PD in vivo. This article summarizes recent PET and SPECT studies of new radiopharmaceuticals and discusses their potential role and perspectives for use in the fields of new drug development and early diagnosis for PD, as well to aid in differential diagnosis and monitoring of the progression of PD.
Palavras-chave
single-photon emission-computed tomography, Parkinson disease, radioactive tracers, lipid metabolism
URI
https://observatorio.fm.usp.br/handle/OPI/4021
Referências
  1. Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x
  2. Aboagye EO, 2010, BRIT J RADIOL, V83, P814, DOI 10.1259/bjr/77317821
  3. Agarwal S, 2012, MOL PHARMACEUT, V9, P678, DOI 10.1021/mp200465c
  4. Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664
  5. Amiry-Moghaddam M, 2005, FASEB J, V19, P1459, DOI 10.1096/fj.04-3515com
  6. Anderson CJ, 2009, CANCER BIOTHER RADIO, V24, P379, DOI 10.1089/cbr.2009.0674
  7. Annovazzi A, 2006, EUR J NUCL MED MOL I, V33, P474, DOI 10.1007/s00259-005-0001-6
  8. Aoyama S, 2000, J NEUROSCI, V20, P5848
  9. Arlicot N, 2008, EUR J NUCL MED MOL I, V35, P2203, DOI 10.1007/s00259-008-0834-x
  10. Arlicot N, 2011, NUCL MED BIOL, V39, P570
  11. Arlicot N, 2010, EUR J NUCL MED MOL I, V37, P2371, DOI 10.1007/s00259-010-1598-7
  12. Armentero MT, 2006, NEUROBIOL DIS, V22, P1, DOI 10.1016/j.nbd.2005.09.010
  13. Asari S, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-35
  14. Badaut Jerome, 2002, Journal of Cerebral Blood Flow and Metabolism, V22, P367
  15. Badaut J, 2010, NEUROSCIENCE, V168, P1047, DOI 10.1016/j.neuroscience.2009.10.030
  16. BAKHEIT AMO, 1995, POSTGRAD MED J, V71, P151
  17. Barbosa MT, 2006, MOVEMENT DISORD, V21, P800, DOI 10.1002/mds.20806
  18. Barksby HE, 2007, CLIN EXP IMMUNOL, V149, P217, DOI 10.1111/j.1365-2249.2007.03441.x
  19. Bartels AL, 2010, PARKINSONISM RELAT D, V16, P57, DOI 10.1016/j.parkreldis.2009.05.005
  20. Bartels AL, 2008, PARKINSONISM RELAT D, V14, P505, DOI 10.1016/j.parkreldis.2007.11.007
  21. Bartels AL, 2008, J NEURAL TRANSM, V115, P1001, DOI 10.1007/s00702-008-0030-y
  22. Bartels AL, 2011, CURR PHARM DESIGN, V17, P2771
  23. Bartels AL, 2009, NEUROBIOL AGING, V30, P1818, DOI 10.1016/j.neurobiolaging.2008.02.002
  24. Battista N, 2007, NEUROBIOL DIS, V27, P108, DOI 10.1016/j.nbd.2007.04.012
  25. Bauer A, 2003, NEUROIMAGE, V19, P1760, DOI 10.1016/S1053-8119(03)00241-6
  26. Bazan NG, 2011, ANNU REV NUTR, V31, P321, DOI 10.1146/annurev.nutr.012809.104635
  27. Benadiba M, 2012, REV BRAS PSIQUIATR, V34, pS125, DOI 10.1016/j.rbp.2012.07.002
  28. Benito C, 2003, J NEUROSCI, V23, P11136
  29. Biegon A, 2010, SYNAPSE, V64, P801, DOI 10.1002/syn.20791
  30. Black YD, 2010, NEUROSCI LETT, V486, P161, DOI 10.1016/j.neulet.2010.09.043
  31. Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038
  32. Booij J, 1999, EUR J NUCL MED, V26, P171, DOI 10.1007/s002590050374
  33. Borghammer P, 2012, J NEUROL SCI, V313, P123, DOI 10.1016/j.jns.2011.09.010
  34. Brenn A, 2011, INT J ALZHEIMERS DIS, V2011
  35. Brooks DJ, 1997, BAILLIERE CLIN NEUR, V6, P69
  36. Bruggemann N, 2010, ARCH NEUROL-CHICAGO, V67, P1357, DOI 10.1001/archneurol.2010.281
  37. Bruno V, 1998, J NEUROSCI, V18, P9594
  38. Cao Q, 2007, EUR J NUCL MED MOL I, V34, P1832, DOI 10.1007/s00259-007-0451-0
  39. Cao W, 2007, NUCL MED COMMUN, V28, P895
  40. Castagnet PI, 2005, J NEUROCHEM, V94, P839, DOI 10.1111/j.1471-4159.2005.032747.x
  41. Casteels C, 2012, EUR J NUCL MED MOL I, V39, P1467, DOI 10.1007/s00259-012-2163-3
  42. Cawthorne C, 2011, BRIT J PHARMACOL, V162, P659, DOI 10.1111/j.1476-5381.2010.01068.x
  43. Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004
  44. Ching Alex Sik Chung, 2012, Insights Imaging, V3, P111, DOI 10.1007/s13244-011-0128-x
  45. Chu WM, 2013, CANCER LETT, V328, P222, DOI 10.1016/j.canlet.2012.10.014
  46. Chung SJ, 2011, MOVEMENT DISORD, V26, P1234, DOI 10.1002/mds.23604
  47. Colabufo NA, 2010, J MED CHEM, V53, P1883, DOI 10.1021/jm900743c
  48. Collins MA, 2013, NEUROTOX RES, V23, P105, DOI 10.1007/s12640-012-9360-5
  49. Dalfo E, 2005, J NEUROPATH EXP NEUR, V64, P816
  50. deWolde H, 1997, J NUCL MED, V38, P1369
  51. DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x
  52. Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495
  53. Do TM, 2012, J ALZHEIMERS DIS, V30, P155, DOI 10.3233/JAD-2012-112189
  54. Dobolyi A, 2012, INT J MOL SCI, V13, P8219, DOI 10.3390/ijms13078219
  55. Dohgu S, 2004, CELL MOL NEUROBIOL, V24, P491, DOI 10.1023/B:CEMN.0000022776.47302.ce
  56. Doorduin J, 2009, MOL IMAGING BIOL, V11, P386, DOI 10.1007/s11307-009-0211-6
  57. Dorner B, 2011, BIOORGAN MED CHEM, V19, P2190, DOI 10.1016/j.bmc.2011.02.039
  58. Drukarch B, 2001, EXPERT OPIN INV DRUG, V10, P1855, DOI 10.1517/13543784.10.10.1855
  59. ElAli A, 2011, NEUROSCIENTIST, V17, P423, DOI 10.1177/1073858410391270
  60. ELLIOTT PNC, 1977, NEUROPHARMACOLOGY, V16, P333, DOI 10.1016/0028-3908(77)90070-3
  61. Ellis CE, 2005, MOL CELL BIOL, V25, P10190, DOI 10.1128/MCB.25.22.10190-10201.2005
  62. Elstner M, 2011, ACTA NEUROPATHOL, V122, P75, DOI 10.1007/s00401-011-0828-9
  63. Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882
  64. Esposito G, 2008, J NUCL MED, V49, P1414, DOI 10.2967/jnumed.107.049619
  65. Evens N, 2011, BIOORGAN MED CHEM, V19, P4499, DOI 10.1016/j.bmc.2011.06.033
  66. Fabelo N, 2011, MOL MED, V17, P1107, DOI 10.2119/molmed.2011.00119
  67. Farkas S, 2012, BRAIN RES BULL, V87, P504, DOI 10.1016/j.brainresbull.2012.02.012
  68. Feldmann M, 1998, SPRINGER SEMIN IMMUN, V20, P211, DOI 10.1007/BF00832008
  69. Ferrari CC, 2006, NEUROBIOL DIS, V24, P183, DOI 10.1016/j.nbd.2006.06.013
  70. Ferre S, 1997, TRENDS NEUROSCI, V20, P482, DOI 10.1016/S0166-2236(97)01096-5
  71. Ferrer I, 2011, J NEURAL TRANSM, V118, P821, DOI 10.1007/s00702-010-0482-8
  72. Ferrer I, 2009, J BIOENERG BIOMEMBR, V41, P425, DOI 10.1007/s10863-009-9243-5
  73. Ferrer I, 2012, NEUROBIOL DIS, V46, P508, DOI 10.1016/j.nbd.2011.10.019
  74. Ferrer I., 2011, PARKINSONS DIS, V2011, DOI 10.4061/2011/708404
  75. Foglio E, 2010, CURR NEUROPHARMACOL, V8, P112, DOI 10.2174/157015910791233150
  76. Fortt R, 2012, NUCL MED BIOL, V39, P1000, DOI 10.1016/j.nucmedbio.2012.03.004
  77. Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391
  78. Fredduzzi S, 2002, J NEUROSCI, V22, P1054
  79. Freeman BD, 2001, EXPERT OPIN BIOL TH, V1, P301, DOI 10.1517/14712598.1.2.301
  80. Freemantle E, 2009, J NUTR HEALTH AGING, V13, P293, DOI 10.1007/s12603-009-0026-9
  81. Frey KA, 2001, ADV NEUROL, V86, P237
  82. Fukumitsu N, 2003, ANN NUCL MED, V17, P511
  83. Fukumoto D, 2012, SYNAPSE, V66, P909, DOI 10.1002/syn.21584
  84. Gallagher CL, 2011, MOVEMENT DISORD, V26, P2032, DOI 10.1002/mds.23778
  85. Gao MZ, 2010, APPL RADIAT ISOTOPES, V68, P1950, DOI 10.1016/j.apradiso.2010.04.030
  86. Garcia-Segura LM, 2008, J NEUROENDOCRINOL, V20, P705, DOI 10.1111/j.1365-2826.2008.01713.x
  87. Gerhard A, 2006, NEUROBIOL DIS, V21, P404, DOI 10.1016/j.nbd.2005.08.002
  88. Gerhard A, 2006, MOVEMENT DISORD, V21, P89, DOI 10.1002/mds.20668
  89. Godoy MCP, 2008, BRAIN, V131, P1880, DOI 10.1093/brain/awn101
  90. Golovko MY, 2009, MOL CELL BIOCHEM, V326, P55, DOI 10.1007/s11010-008-0008-y
  91. Gomes CV, 2011, BBA-BIOMEMBRANES, V1808, P1380, DOI 10.1016/j.bbamem.2010.12.001
  92. Gomez C, 2007, FRONT BIOSCI, V12, P1079, DOI 10.2741/2128
  93. Gonzalez-Cuyar LF, 2011, CURR NEUROL NEUROSCI, V11, P455, DOI 10.1007/s11910-011-0212-0
  94. Gordon R, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-82
  95. Gowran A, 2011, CNS NEUROSCI THER, V17, P637, DOI 10.1111/j.1755-5949.2010.00195.x
  96. Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940
  97. Hao CS, 2010, TOXICOL LETT, V198, P225, DOI 10.1016/j.toxlet.2010.06.023
  98. Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597
  99. Hauser RA, 2005, DRUG AGING, V22, P471, DOI 10.2165/00002512-200522060-00002
  100. Hickey P, 2012, CURR NEUROL NEUROSCI, V12, P376, DOI 10.1007/s11910-012-0279-2
  101. Hiltunen M, 2006, Minerva Endocrinol, V31, P61
  102. Horti AG, 2006, J NUCL MED, V47, P1689
  103. Hu S, 2012, MOL IMAGING BIOL, V14, P762, DOI 10.1007/s11307-012-0551-5
  104. Ishiwata K, 2000, ANN NUCL MED, V14, P81, DOI 10.1007/BF02988585
  105. Jager R, 2012, BIOCH RES INT
  106. Kachroo A, 2005, J NEUROSCI, V25, P10414, DOI 10.1523/JNEUROSCI.3660-05.2005
  107. Kannan P, 2011, ACS CHEM NEUROSCI, V2, P82, DOI 10.1021/cn100078a
  108. Katona I, 2008, NAT MED, V14, P923, DOI 10.1038/nm.f.1869
  109. Keane PC, 2011, PARKINSONS DIS, V2011, P716871
  110. Knudsen Gerber DS, 2011, CONSULT PHARM, V26, P48
  111. Kong FL, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/671708
  112. Kortekaas R, 2005, ANN NEUROL, V57, P176, DOI 10.1002/ana.20369
  113. Kugaya A, 2000, ANN NUCL MED, V14, P1, DOI 10.1007/BF02990472
  114. Kuppers E, 2008, EUR J NEUROSCI, V28, P2173, DOI 10.1111/j.1460-9568.2008.06531.x
  115. Leng Y, 2006, J NEUROSCI, V26, P7502, DOI 10.1523/JNEUROSCI.0096-06.2006
  116. Li GL, 2012, BRIT J CLIN PHARMACO, V73, P706, DOI 10.1111/j.1365-2125.2011.04137.x
  117. Lim JH, 2008, PHARMACOL RES, V57, P325, DOI 10.1016/j.phrs.2008.03.004
  118. Lin PY, 2012, J CLIN PSYCHIAT, V73, P1245, DOI 10.4088/JCP.11r07546
  119. Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
  120. Liu H, 2012, ARQ NEURO-PSIQUIAT, V70, P214, DOI 10.1590/S0004-282X2012000300012
  121. Liu ZL, 2011, NUCL MED BIOL, V38, P795, DOI 10.1016/j.nucmedbio.2011.02.012
  122. Lou ZY, 2011, MOL IMMUNOL, V49, P453, DOI 10.1016/j.molimm.2011.09.016
  123. Lubberink M, 2007, J CEREBR BLOOD F MET, V27, P424, DOI 10.1038/sj.jcbfm.9600349
  124. Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400
  125. Luchtman DW, 2012, BEHAV BRAIN RES, V226, P386, DOI 10.1016/j.bbr.2011.09.033
  126. Luurtsema G, 2009, NUCL MED BIOL, V36, P643, DOI 10.1016/j.nucmedbio.2009.03.004
  127. Luurtsema G, 2005, NUCL MED BIOL, V32, P87, DOI 10.1016/j.nucmedbio.2004.06.007
  128. Luurtsema G, 2003, NUCL MED BIOL, V30, P747, DOI 10.1016/S0969-8051(03)00078-7
  129. Machado A., 2011, PARKINSONS DIS, V2011
  130. Maia S, 2012, SYNAPSE, V66, P573, DOI 10.1002/syn.21543
  131. Mairinger S, 2012, NUCL MED BIOL, V39, P1219, DOI 10.1016/j.nucmedbio.2012.08.005
  132. Malagelada C, 2010, J NEUROSCI, V30, P1166, DOI 10.1523/JNEUROSCI.3944-09.2010
  133. Martic-Kehl MI, 2012, EUR J NUCL MED MOL I, V39, P1492, DOI 10.1007/s00259-012-2175-z
  134. MATTAMMAL MB, 1995, J NEUROCHEM, V64, P1645
  135. Mattner F, 2011, EUR J NUCL MED MOL I, V38, P1516, DOI 10.1007/s00259-011-1784-2
  136. Meng QJ, 2010, EUR J PHARMACOL, V649, P127, DOI 10.1016/j.ejphar.2010.09.046
  137. Mishina M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017338
  138. MOGI M, 1994, NEUROSCI LETT, V180, P147, DOI 10.1016/0304-3940(94)90508-8
  139. MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3
  140. MOGI M, 1995, NEUROSCI LETT, V193, P129, DOI 10.1016/0304-3940(95)11686-Q
  141. Mollereau B, 2013, CELL DEATH DIFFER, V20, P181, DOI 10.1038/cdd.2012.82
  142. Montgomery SL, 2012, J NEUROIMMUNE PHARM, V7, P42, DOI 10.1007/s11481-011-9287-2
  143. Morale MC, 2008, BRAIN RES REV, V57, P431, DOI 10.1016/j.brainresrev.2007.10.011
  144. Morissette M, 2008, MOL CELL ENDOCRINOL, V290, P60, DOI 10.1016/j.mce.2008.04.008
  145. Muftuoglu M, 2004, MOVEMENT DISORD, V19, P544
  146. Munnink THO, 2011, J NUCL MED, V52, P2001, DOI 10.2967/jnumed.111.092809
  147. Nakaso K, 2008, NEUROSCI LETT, V432, P146, DOI 10.1016/j.neulet.2007.12.034
  148. Nguyen QD, 2012, EUR J CANCER, V48, P432, DOI 10.1016/j.ejca.2011.11.033
  149. Nicchia GP, 2003, FASEB J, V17, P1508, DOI 10.1096/fj.02-1183fje
  150. Noguchi J, 1998, J NUCL MED, V39, P498
  151. Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8
  152. ONDA K, 1994, ACTA NEUROPATHOL, V87, P586
  153. Ongini E, 1996, TRENDS PHARMACOL SCI, V17, P364, DOI 10.1016/S0165-6147(96)10045-6
  154. Ouchi Y, 2005, ANN NEUROL, V57, P168, DOI 10.1002/ana.20338
  155. Ouellet M, 2009, NEUROCHEM INT, V55, P476, DOI 10.1016/j.neuint.2009.04.018
  156. Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468
  157. Park Nguyen H, 2012, JAAPA, V25, P73
  158. Paul S, 2011, J NUCL MED, V52, P1293, DOI 10.2967/jnumed.111.088005
  159. Pavese N, 2012, NEUROIMAGE, V59, P1080, DOI 10.1016/j.neuroimage.2011.09.034
  160. Pifferi F, 2011, NUTR NEUROSCI, V14, P51, DOI 10.1179/1476830510Y.0000000001
  161. Pimlott SL, 2011, CHEM SOC REV, V40, P149, DOI 10.1039/b922628c
  162. Pinna A, 2005, EUR J PHARMACOL, V512, P157, DOI 10.1016/j.ejphar.2005.01.057
  163. Plaat B, 1999, EUR J NUCL MED, V26, P328, DOI 10.1007/s002590050394
  164. Puren AJ, 1998, J CLIN INVEST, V101, P711, DOI 10.1172/JCI1379
  165. Quesada A, 2008, DEV NEUROBIOL, V68, P632, DOI 10.1002/dneu.20609
  166. Quilty MC, 2006, EXP NEUROL, V199, P249, DOI 10.1016/j.expneurol.2005.10.018
  167. Rahmim A, 2008, NUCL MED COMMUN, V29, P193, DOI 10.1097/MNM.0b013e3282f3a515
  168. Ramirez BG, 2005, J NEUROSCI, V25, P1904, DOI 10.1053/JNEUROSCI.4540-04.2005
  169. Ramlackhansingh AF, 2011, NEUROLOGY, V76, P1811, DOI 10.1212/WNL.0b013e31821ccce4
  170. Rapoport SI, 2011, PROSTAG OTH LIPID M, V96, P109, DOI 10.1016/j.prostaglandins.2011.06.003
  171. Rapoport SI, 2003, J PEDIATR, V143, pS26, DOI 10.1067/S0022-3476(03)00399-8
  172. Rapoport SI, 2008, J NUTR, V138, P2515
  173. Rapoport SI, 2001, J LIPID RES, V42, P678
  174. Rentzos M, 2009, ACTA NEUROL SCAND, V119, P332, DOI 10.1111/j.1600-0404.2008.01103.x
  175. Reshef A, 2010, J NUCL MED, V51, P837, DOI 10.2967/jnumed.109.063917
  176. ROBINSON PJ, 1992, BRAIN RES REV, V17, P187, DOI 10.1016/0165-0173(92)90016-F
  177. Roselli CF, J STEROID BIOCH MOL, V106, P143
  178. Roussa E, 2009, ADV EXP MED BIOL, V651, P81
  179. Ryoo HD, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008797
  180. Saldanha CJ, 2009, FRONT NEUROENDOCRIN, V30, P106, DOI 10.1016/j.yfrne.2009.04.016
  181. Scarselli M, 2001, ADV NEUROL, V86, P367
  182. Schinkel AH, 1999, ADV DRUG DELIVER REV, V36, P179, DOI 10.1016/S0169-409X(98)00085-4
  183. Schoder H, 2004, SEMIN NUCL MED, V34, P274, DOI 10.1053/j.semnuclmed.2004.06.004
  184. Scotter EL, 2010, BRIT J PHARMACOL, V160, P480, DOI 10.1111/j.1476-5381.2010.00735.x
  185. Seibyl JP, 2008, SEMIN NUCL MED, V38, P274, DOI 10.1053/j.semnuclmed.2008.03.001
  186. Shaftel SS, 2007, J CLIN INVEST, V117, P1595, DOI 10.1172/JCI31450
  187. Shaftel SS, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-7
  188. Sharon R, 2003, J BIOL CHEM, V278, P49874, DOI 10.1074/jbc.M309127200
  189. Shim JH, 2011, MITOCHONDRION, V11, P707, DOI 10.1016/j.mito.2011.05.013
  190. Sidhu A, 2004, ANN NY ACAD SCI, V1035, P250, DOI 10.1196/annals.1332.016
  191. Singer Carlos, 2012, Cleve Clin J Med, V79 Suppl 2, pS3, DOI 10.3949/ccjm.79.s2a.01
  192. Skaddan MB, 2012, NUCL MED BIOL, V39, P1058, DOI 10.1016/j.nucmedbio.2012.03.011
  193. Stoessl AJ, 2007, PARKINSONISM RELAT D, V13, pS421, DOI 10.1016/S1353-8020(08)70041-5
  194. Stoll G, 2000, J NEURAL TRANSM-SUPP, P81
  195. Svenningsson P, 1999, PROG NEUROBIOL, V59, P355, DOI 10.1016/S0301-0082(99)00011-8
  196. Tait JF, 2008, J NUCL MED, V49, P1573, DOI 10.2967/jnumed.108.052803
  197. Takahashi K, 2011, BIOORGAN MED CHEM, V19, P1464, DOI 10.1016/j.bmc.2010.12.057
  198. Tang CC, 2010, J NEUROSCI, V30, P1049, DOI 10.1523/JNEUROSCI.4188-09.2010
  199. Tansey MG, 2007, EXP NEUROL, V208, P1, DOI 10.1016/j.expneurol.2007.07.004
  200. Tapia-Gonzalez S, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-72
  201. Terry G, 2008, NEUROIMAGE, V41, P690, DOI 10.1016/j.neuroimage.2008.03.004
  202. Terry GE, 2010, J NUCL MED, V51, P112, DOI 10.2967/jnumed.109.067074
  203. Terry GE, 2009, NEUROIMAGE, V48, P362, DOI 10.1016/j.neuroimage.2009.06.059
  204. Thambisetty M, 2012, J CEREBR BLOOD F MET, V32, P676, DOI 10.1038/jcbfm.2011.171
  205. Toornvliet R, 2006, CLIN PHARMACOL THER, V79, P540, DOI 10.1016/j.clpt.2006.02.004
  206. Turkman N, 2012, NUCL MED BIOL, V39, P593, DOI 10.1016/j.nucmedbio.2011.10.019
  207. Turkman N, 2011, BIOORGAN MED CHEM, V19, P5698, DOI 10.1016/j.bmc.2011.07.062
  208. Van Laere K, 2012, NEUROBIOL AGING, V33
  209. VanBrocklin HF, 2007, NUCL MED BIOL, V34, P109, DOI 10.1016/j.nucmedbio.2006.10.005
  210. van Dyck CH, 2000, NEUROBIOL AGING, V21, P497, DOI 10.1016/S0197-4580(00)00152-4
  211. van Waarde A, 2009, J MED CHEM, V52, P4524, DOI 10.1021/jm900485a
  212. Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357
  213. Visser FC, 2001, CORONARY ARTERY DIS, V12, pS12
  214. Vortherms TA, 2004, J PHARMACOL EXP THER, V308, P221, DOI 10.1124/jpet.103.057083
  215. Wanek T, 2012, J CEREBR BLOOD F MET, V32, P2002, DOI 10.1038/jcbfm.2012.112
  216. Wang M, 2012, BIOORG MED CHEM LETT, V22, P1569, DOI 10.1016/j.bmcl.2011.12.136
  217. Willmann JK, 2008, NAT REV DRUG DISCOV, V7, P591, DOI 10.1038/nrd2290
  218. Wilson AA, 2011, NUCL MED BIOL, V38, P247, DOI 10.1016/j.nucmedbio.2010.08.001
  219. Wyffels L, 2010, NUCL MED BIOL, V37, P665, DOI 10.1016/j.nucmedbio.2010.03.009
  220. Wyffels L, 2009, J MED CHEM, V52, P4613, DOI 10.1021/jm900324e
  221. Xiong HQ, 2009, J NEUROSCI, V29, P5463, DOI 10.1523/JNEUROSCI.5103-08.2009
  222. Y uzuki, 2012, J NEUROIMAGING, V23, P219
  223. Yamada M, 2010, BIOCHEM BIOPH RES CO, V402, P312, DOI 10.1016/j.bbrc.2010.10.023
  224. Yasuno F, 2008, NEUROPSYCHOPHARMACOL, V33, P259, DOI 10.1038/sj.npp.1301402
  225. Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696
  226. Yu M, 2009, EUR J NUCL MED MOL I, V36, P63, DOI 10.1007/s00259-008-0909-8
  227. Zhang CD, 2010, J NUTR, V140, P858, DOI 10.3945/jn.109.114884
  228. Zhang L, 2012, NEURAL REGEN RES, V7, P141, DOI 10.3969/j.issn.1673-5374.2012.02.011
  229. Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com
  230. Zubal G, 2009, SOC NUCL MED ANN M, V50, P1221

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/21
Carregar mais